Table 6.
Liver transplant recipients with HBV infection who received either FK506 or CyA as the baseline immunosuppressive drug.
| Characteristics | FK506 | CyA |
|---|---|---|
| No. of patients | 65 | 59a |
| HBV serology | ||
| HBsAg | 100% | 100% |
| HBeAg | 53% | 46% |
| Anti-delta | 17.1% | 27.3% |
| Patients with tumor | 21.5% | 19% |
| Follow-up (range-months) | 26–64 | 19–68 |
| Death | ||
| Disease related | 13 (20%) | 14 (24%) |
| Tumor related | 2 (3%) | 3 (5%) |
| Others | 7 (10.8%) | 12 (20%) |
| Total | 22 (33.8%) | 29 (49%) |
| Retransplantation | ||
| Disease related | 5 (7.7%) | 7 (11.9%) |
| Nondisease related | 8 (12.3%) | 10 (16.9%) |
| Total | 13 (20%) | 17 (28.8%) |
| Disease recurrenceb | ||
| 6 months HBIG | 20/38 (52.6%) | — |
| ≤3 months HBIG | 12/15 (80%) | 19/25 (76%) |
| No HBIG | 5/8 (62.5%) | 18/20 (90%) |
| Overall | 37/61 (60.7%) | 37/45 (82%)c |
a
8 patients had fulminant hepatic failure
b
Patients who survived beyond 60 days, HBIG=hepatitis B immune globulin
c
p<0.05